Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 11, 2012, Pages 1716-1726

  Finke, Jürgen ^a   Schmoor, Claudia ^a   Bethge, Wolfgang A ^b   Ottinger, Hellmut D ^c   Stelljes, Matthias ^d   Zander, Axel R ^e   Volin, Liisa ^f   Heim, Dominik A ^g   Schwerdtfeger, Rainer ^h   Kolbe, Karin ⁱ   Mayer, Jiri ^j   Maertens, Johan A ^k,s   Linkesch, Werner ^l   Holler, Ernst ^m   Koza, Vladimir ⁿ   Bornhäuser, Martin ^o   Einsele, Hermann ^p   Bertz, Hartmut ^a   Grishina, Olga ^a   Socié, Gérard ^q,s   Schneeberger, H ^r   Borner G ^r   Gamperl, H J ^r   Jauch, J ^r   Petan, J ^r   Kainz, A ^r   Schmoor, C ^a   Grishina, O ^a   Müller, Ch ^a   Scheele, J ^a   Schilling, B ^a   Kaufmann, M ^a   Tostmann, R ^a   Kollmer, A ^a   Nuss, S ^a   Wenig, C ^a   Bertz, H ^s   Egger, M ^s   Bethge, W A ^s   Einsele, H ^s   Muller R K F ^s   Hntschel M ^s   Ottinger, H D ^s   Trenschel, R ^s   Stelljes, M ^s   Zander, A R ^s   Kroger N M ^s   Ayuketang, F A ^s   Wolschke, C ^s   Schwerdtfeger, R ^s   Kaltenhuser J ^s   Stubig T ^s   Taube, R H ^s   Kolbe, K ^s   Thomas, S ^s   Ullmann, A ^s   Schulze Bergkamen, A ^s   Holler, E ^s   Hahn, J ^s   Bornhuser M ^s   Kolb, H J ^s   Reibke, R ^s   Wandt, H ^s   Schaefer Eckart, K ^s   Gluckman, E ^s   Esperou, H ^s   Robin, M ^s   Michallet, M ^s   Nicolini, F ^s   Buzyn A , ^s   Rubio, M T ^s   Yakoub Agha, I ^s   Jouet, J P ^s   Petillon, M O ^s   Bordigoni, P ^s   Clement, L ^s   Salmon, A ^s   Feugier, P ^s   Ruutu, T ^s   Volin, L ^s   Juvonen, E ^s   Nihtinen, A ^s   Remes, K ^s   Putkonen, M ^s   Itl M ^s   Kauppila, M ^s   Mayer, J ^s   Krejci, M ^s   Brychtova, Y ^s   Koza, V ^s   Karas, M ^s   Voglova, J ^s   Lebavy, J ^s   Zak, P ^s   Heim, D ^s   Gratwohl, A ^s   Passweg, J ^s   Arber, C ^s   Tsakiris, A ^s   Linkesch, W ^s   Reitter, S ^s   Staber, P B ^s   Lutz, D ^s   Krieger, O ^s   Theunissen, K ^s   Boogaerts, M ^s   Verhoef, G ^s   Rowe, J ^s   Rosenvald Zuckermann, T ^s   Shapira, M ^s   Or, R ^s   Resnik, I ^s   Nagler, A ^s   Shimoni, A ^s   Yerushalmi, R ^s   Sierra, J ^s   Valcarcel, D ^s   Perez Simon, J A ^s   Astorga, M ^s   Bosi, A ^s   Guidi, S ^s   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY HOSPITAL GRAZ   (Austria)

^m UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^p UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^q SAINT LOUIS HOSPITAL   (France)

^r Fresenius Biotech   (Germany)

^s Fresenius Biotech GmbH ^*

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease prophylaxis; HLA matching

Indexed keywords

ANTITHYMOCYTE GLOBULIN FRESENIUS; CYCLOSPORIN A; IMMUNOMODULATING AGENT; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84867404950     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.001     Document Type: Article

References (31)

1. Baldomero H., Gratwohl M., Gratwohl A., et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011, 46:485-501.
2. Sorror M.L., Leisenring W., Deeg H.J., Martin P.J., Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005, 11:814-815.
3. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009, 27:1644-1652.
4. Dehn J., Arora M., Spellman S., et al. Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match. Biol Blood Marrow Transplant 2008, 14:1334-1340.
5. Weisdorf D.J., Nelson G., Lee S.J., et al. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant 2009, 15:1475-1478.
6. Gratwohl A., Brand R., Niederwieser D., et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 2011, 29:1980-1986.
7. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
8. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
9. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
10. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
11. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
12. Petersdorf E.W., Malkki M., Gooley T.A., Martin P.J., Guo Z. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007, 4:e8.
13. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:885-892.
14. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998, 92:3515-3520.
15. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104:961-968.
16. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
17. Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
18. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007, 13:1461-1468.
19. Craddock C., Labopin M., Pillai S., et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011, 25:808-813.
20. Craddock C., Nagra S., Peniket A., et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010, 95:989-995.
21. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
22. Simon R., Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69:979-985.
23. Socié G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
24. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
25. Pulsipher M.A., Chitphakdithai P., Logan B.R., et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009, 114:2606-2616.
26. Anasetti C., Logan B.R., Lee S.J., et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with Filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial [abstract]. ASH Annual Meeting Abstracts 2011, 118:1.
27. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
28. Marks R., Potthoff K., Hahn J., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
29. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
30. Platzbecker U., Thiede C., Füssel M., et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006, 20:707-714.
31. Schlenk R.F., Döhner K., Mack S., et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010, 28:4642-4648.